BioSpace News Archive

Cara Therapeutics, Inc. announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020, at 4:30 p.m. ET to report first quarter 2020 financial results and provide a corporate update.

Neos Therapeutics, Inc., a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, announced that it will report its first quarter 2020 financial results at the closing of U.S. financial markets on Monday, May 11, 2020.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced that it will report its first quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, May 13, 2020.

GenMark Diagnostics, Inc., a leading provider of automated, multiplex molecular diagnostic testing systems, announced that Scott Mendel has been appointed President and Chief Executive Officer effective immediately.

Fulgent Genetics, a provider of comprehensive genetic testing and Next Generation Sequencing solutions, announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020.

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that it will report first quarter 2020 financial results on Monday, May 11, 2020, before the market open.

Semler Scientific, Inc., a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, reported financial results for the three months ended March 31, 2020.

Synlogic, Inc., a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced that the Company will release its first quarter 2020 financial results before the market opens on Friday, May 8, 2020.

CHI Franciscan hospitals recognized for patient safety with consecutive top-scoring of ‘A’ and ‘B’ grades in recent Leapfrog Hospital Safety Grades

Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2020.